[1]胡志民,刘金霞,娄金峰.ATRX及Ki-67在脑胶质瘤中表达及临床意义[J].中国临床神经外科杂志,2024,29(09):544-547.[doi:10.13798/j.issn.1009-153X.2024.09.008]
　HU Zhi-min,LIU Jin-xia,LOU Jin-feng.Expression of ATRX and Ki-67 in glioma and their clinical significance[J].,2024,29(09):544-547.[doi:10.13798/j.issn.1009-153X.2024.09.008]
点击复制

ATRX及Ki-67在脑胶质瘤中表达及临床意义()

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年09期
页码:
544-547
栏目:
论著
出版日期:
2024-09-30

文章信息/Info

Title:
Expression of ATRX and Ki-67 in glioma and their clinical significance
文章编号:
1009-153X（2024）09-0544-04
作者:
胡志民; 刘金霞; 娄金峰
457000 河南，濮阳市人民医院神经外科（胡志民），病理科（刘金霞）；450000 郑州，郑州大学第二附属医院神经外科（娄金峰）
Author(s):
HU Zhi-min1;  LIU Jin-xia2;  LOU Jin-feng3
1. Department of Neurosurgery, Puyang People's Hospital, Puyang 457000, China; 2. Department of Pathology, Puyang People's Hospital, Puyang 457000, China; 3. Department of Neurosurgery, Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China
关键词:
胶质瘤; ATRX; Ki-67; 基因表达; 预后
Keywords:
Glioma;  ATRX;  Ki-67;  Gene expression;  Prognosis
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2024.09.008
文献标志码:
A
摘要:
目的 探讨ATRX及Ki-67在人脑胶质瘤中表达情况及临床意义。方法 收集2018年1月至2023年1月手术切除并经术后病理检查确诊的51例脑胶质瘤标本，采用免疫组化染色检测ATRX及Ki-67的表达。术后随访0.5~50个月，中位数16个月（IQR：5~28个月），记录病人生存情况。结果 51例胶质瘤中，WHO分级Ⅰ级3例，Ⅱ级13例，Ⅲ级16例，Ⅳ级19例。WHO分级Ⅲ、Ⅳ级胶质瘤Ki-67阳性率（80.0%，28/35）明显高于WHO分级Ⅰ、Ⅱ级胶质瘤（50.0%，8/16；P=0.029）；WHO分级Ⅲ、Ⅳ级胶质瘤ATRX阳性率（68.6%，24/35）低于WHO分级Ⅰ、Ⅱ级胶质瘤（87.5%，14/16)），但无统计学差异（P=0.185）。多因素Cox回归分析显示，Ki-67阴性表达（RR=0.408；95% CI 0.214~0.778；P=0.006）是胶质瘤生存预后不良的独立保护因素，ATRX阴性表达（RR=2.189；95% CI 0.082~4.431；P=0.029）是胶质瘤生存预后不良的独立影响因素。Kaplan-Meier生存曲线分析显示，Ki-67阴性表达、ATRX阳性表达胶质瘤中位生存期明显延长（P<0.05）。结论 ATRX及Ki-67表达与胶质瘤病理级别和病人预后相关，可作为胶质瘤病人病理分级及预后评估的参考指标。
Abstract:
Objective To investigate the expression of ATRX and Ki-67 in human gliomas and their clinical significance. Methods Fifty-one specimens of gliomas that were surgically resected and diagnosed by postoperative pathological examination from January 2018 to January 2023 were collected. The expression of ATRX and Ki-67 was detected by immunohistochemical staining. The postoperative follow-up period ranged from 0.5 to 50 months, with a median of 16 months (IQR: 5~28 months), and the survival status of the patients was recorded. Results Of the 51 glioma patients, 3 were WHO grade Ⅰ, 13 were grade Ⅱ, 16 were grade Ⅲ, and 19 were grade Ⅳ. The positive rate of Ki-67 in WHO grade Ⅲ and Ⅳ gliomas (80.0%, 28/35) was significantly higher than that in WHO grade Ⅰ and Ⅱ gliomas (50.0%, 8/16; P=0.029); the positive rate of ATRX in WHO grade Ⅲ and Ⅳ gliomas (68.6%, 24/35) was lower than that in WHO grade Ⅰ and Ⅱ gliomas (87.5%, 14/16), but without statistical significance (P=0.185). Multivariate Cox regression analysis revealed that negative expression of Ki-67 (RR=0.408; 95% CI 0.214~0.778; P=0.006) was an independent protective factor for poor prognosis of glioma, and negative expression of ATRX (RR=2.189; 95% CI 0.082~4.431; P=0.029) was an independent risk factor for poor prognosis of glioma. Kaplan-Meier survival curve analysis demonstrated that the median survival times of gliomas with negative expression of Ki-67 and positive expression of ATRX were significantly prolonged (P<0.05). Conclusion The expressions of ATRX and Ki-67 are correlated with the pathological grade and prognosis of glioma patients and can serve as reference indicators for pathological classification and prognosis evaluation of glioma patients.

参考文献/References:

[1]CLOUGHESY TF, LANDOLFI J, VOGELBAUM MA, et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511+Toca FC[J]. NeuroOncol, 2018, 20(10): 1383-1392.
[2]LOUIS DN, PERRY A, WESSELING P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251.
[3]JALAL JA, ROWANDIZY AIS, ISMAEL AT. Immunohistochemical expression of ATRX in gliomas[J]. Cell Mol Biol (Noisy-le-grand),2020, 66(7): 131-135.
[4]GRANDIN N, PEREIRA B, COHEN C, et al. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas[J]. Acta Neuropathol Commun, 2019, 7(1): 175.
[5]SU YL, LI H, CHAO B, et al. Role of TERT promoter mutation and ATRX expression level in prognosis assessement of patients with glioma[J]. Chin J Clin Neurosurg, 2021, 26(4): 246-249.苏优勒，李　昊，朝　博，等. TERT启动子突变、ATRX表达水平在人脑胶质瘤病人预后评估中的作用[J]. 中国临床神经外科杂志，2021，26（4）：246-249.
[6]LIU J, ZHANG X, YAN X, et al. Significance of TERT and ATRX mutations in glioma[J]. Oncol Lett, 2019, 17(1): 95-102.
[7]DAHLROT RH, BANGS JA, PETERSEN JK, et al. Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells[J]. Sci Rep, 2021, 11(1): 17918.
[8]XU G, LI C, WANG Y, et al. Correlation between preoperativeinflammatory markers, Ki-67 and the pathological grade of glioma[J]. Medicine (Baltimore), 2021, 100(36): e26750.
[9]WANG K, HA T, CHEN X, et al. A combined diffusion tensor imaging and Ki-67 labeling index study for evaluating the extent of tumor infiltration using the F98 rat glioma model[J]. J Neurooncol,2018, 137(2): 259-268.
[10]WONG E, NAHAR N, HAU E, et al. Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma[J]. Asia Pac J Clin Oncol, 2019, 15(1): 5-9.
[11]LI S, ZHENG Y, SUN W, et al. Glioma grading, molecular feature classification, and microstructural characterization using MR diffusional variance decomposition (DIVIDE) imaging[J]. Eur Radiol,2021, 31(11): 8197-8207.
[12]CUI Y, ZENG W, JIANG H, et al. Higher Cho/NAA ratio in post-operative peritumoral edema zone is associated with earlier recurrence of glioblastoma[J]. Front Neurol, 2020, 11: 592155.
[13]XIE Y, TAN Y, YANG C, et al. Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis[J]. Cancer Biol Med, 2019, 16(4): 784-796.
[14]BABIKIR H, WANG L, SHAMARDANI K, et al. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma[J]. Genome Biol, 2021, 22(1): 311.
[15]HU C, WANG K, DAMON C, et al. ATRX loss promotes immuno-suppressive mechanisms in IDH1 mutant glioma[J]. Neuro Oncol, 2022, 24(6): 888-900.

相似文献/References:

[1]常英男　王　策　赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
　CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(09):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[2]赛　克　陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[3]许　耿　路俊锋　杨　忠　施建斌　吴秋月　王　烨　庄冬晓　吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
　XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(09):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[4]李剑峰　陈银生　赛　克　张湘衡　柯　超　杨群英　牟永告　许海雄　陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
　LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(09):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[5]云德波　杨宇焦　张　逵　范润金　张　渊　杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性 癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
　YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(09):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]黄书岚　成于思　王　辉　汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞 增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
　HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(09):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[7]林　雨　张　恺　李　帅　杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[8]戴黎明　徐成仕　王泽芬　曹长军　李志强.VEGF单抗对低氧环境下C6胶质瘤细胞侵袭性的影响[J].中国临床神经外科杂志,2016,(04):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
　DAI Li-ming,XU Cheng-shi,WANG Ze-fen,et al.Effect of nonoclonal antibody of VEGF on C6 glioma cells invasiveness under hypoxia and the role of FAK/Pyk2[J].,2016,(09):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
[9]彭泽生　田道锋　张申起　陈谦学.miR-370-3p对胶质母细胞瘤U87-MG细胞株增殖能力的影响[J].中国临床神经外科杂志,2016,(04):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
　PENG Ze-sheng,TIAN Dao-feng,ZHANG Shen-qi,et al.Effects of MircoRNA-370-3p on proliferation of glioma cell line U87-MG and its potential mechanism[J].,2016,(09):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
[10]冯　驰　郭双毅　程龙海　罗　杰.氯喹通过抑制自噬促进TRAIL诱导的胶质瘤细胞凋亡[J].中国临床神经外科杂志,2016,(04):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]
　FENG Chi,GUO Shuang-yi,CHENG Long-hai,et al.Chloroquine promotes TRAIL-induced apoptosis of glioma cells through inhibition of autophagy[J].,2016,(09):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]

备注/Memo

备注/Memo:
（2023-10-16收稿，2024-06-27修回）
基金项目：2022年河南省医学科技攻关联合共建项目（LHGJ20220467）
通信作者，娄金峰，Email：huzm2023@163.com
更新日期/Last Update: 2024-09-30